Key Issues for State Medicaid Programs When the COVID-19 Public Health Emergency Ends

As a result of the COVID-19 Public Health Emergency (PHE) , states have experienced increased enrollment along with administrative challenges. After the PHE ends, states are likely to have renewal and redetermination backlogs and will face decisions around continuing temporary policy changes. This brief highlights key issues from the new CMS guidance to states on how to unwind emergency authorities and resume normal eligibility and enrollment operations.

Analysis of Recent National Trends in Medicaid and CHIP Enrollment

This data note looks at national and state-by-state Medicaid and CHIP preliminary enrollment data through September 2020, as states were still in the early stages of experiencing the health and economic effects of the coronavirus pandemic. After declines in enrollment from 2017 through 2019, preliminary data show that total enrollment grew to 77.3 million in September, an increase of 6.1 million from actual enrollment in February 2020 (8.6%), right before the pandemic and when enrollment began to steadily increase.

A Dozen Facts About Medicare Advantage in 2020

Medicare Advantage enrollment has grown rapidly over the past decade, and Medicare Advantage plans have taken on a larger role in the Medicare program. More than 24 million Medicare beneficiaries (36%) are enrolled in Medicare Advantage plans in 2020. This data analysis provides updated information about Medicare Advantage enrollment trends, premiums, and out-of-pocket limits. It also includes analyses of Medicare Advantage plans’ extra benefits and prior authorization requirements. The analysis also highlights changes pertaining to Medicare Advantage coverage that have occurred in 2020 in response to the COVID-19 crisis.

Analysis of Recent National Trends in Medicaid and CHIP Enrollment

This data note looks at national and state-by-state Medicaid and CHIP preliminary enrollment data through August 2020, as states were still in the early stages of experiencing the health and economic effects of the coronavirus pandemic. After declines in enrollment from 2017 through 2019, preliminary data show that total enrollment grew to 76.5 million in August, an increase of 5.3 million from actual enrollment in February 2020 (7.4%), right before the pandemic and when enrollment began to steadily increase.

Medicaid Maintenance of Eligibility (MOE) Requirements: Issues to Watch

Federal legislation provides a temporary increase in federal Medicaid matching rates to states conditioned on states providing continuous eligibility for existing enrollees and meeting certain other eligibility requirements. This brief provides an overview of these maintenance of eligibility (MOE) requirements, examines what happens when the MOE expires, and discusses key issues to consider looking ahead.

Growth in Medicaid MCO Enrollment during the COVID-19 Pandemic

This data note looks at state Medicaid managed care enrollment data through September 2020 to assess the impact of the COVID-19 pandemic and economic crisis on Medicaid enrollment. Data collected for 30 states show Medicaid managed care enrollment increased to 11.3% from March 2020 through September 2020. The rate accelerated from the 4.1% reported for 27 states from March 2020 through May 2020 and reversed trends from March 2019 to March 2020 when aggregate growth declined. These trends mirror national enrollment trends that show enrollment growth has been accelerating post-pandemic.

Analysis of Recent National Trends in Medicaid and CHIP Enrollment

This data note looks at national and state-by-state Medicaid and CHIP preliminary enrollment data through July 2020, as states were still in the early stages of experiencing the health and economic effects of the coronavirus pandemic. After declines in enrollment from 2017 through 2019, preliminary data show that total enrollment grew to 75.5 million in July, an increase of 4.3 million from actual enrollment February 2020 (6.1%), right before the pandemic and when enrollment began to steadily increase.

Medicare Advantage 2021 Spotlight: First Look

For 2021, the average Medicare beneficiary has access to 33 Medicare Advantage plans, the largest number of options available in the last decade, and can choose from plans offered by eight firms. Among the majority of Medicare Advantage plans that cover prescription drugs, 54 percent will charge no premium in addition to the monthly Medicare Part B premium. As in previous years, the vast majority of Medicare Advantage plans will offer supplemental fitness, dental, vision, and hearing benefits. In addition, virtually all will also offer telehealth benefits in 2021.

Election 2020: State Health Care Snapshots

Health care is a top issue for voters in the 2020 election. To understand the health care landscape in which the 2020 election policy debates will unfold, these state health care snapshots provide data across a variety of health policy subjects, including health care costs, health coverage—Medicaid, Medicare, private insurance—and the uninsured, women’s health, health status, and access to care.

Analysis of Recent National Trends in Medicaid and CHIP Enrollment

This data note looks at national and state-by-state Medicaid and CHIP preliminary enrollment data through June 2020, as states were still in the early stages of experiencing the health and economic effects of the coronavirus pandemic. After declines in enrollment from 2017 through 2019, preliminary data show that total enrollment grew to 74.6 million in June, an increase of 3.4 million from actual enrollment February 2020 (4.8%), right before the pandemic and when enrollment began to steadily increase.

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

Shots: 

  • The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID
  • Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the patients participating in the study. DSMB also considered the impact of the ACTIV-3 study pause on ACTIV-2 and did not recommend any changes to that study’s design or enrollment
  • Lilly is testing both single Ab therapy, as well as combinations of Abs as potential therapeutics for COVID-19, across two different patient populations in P-II BLAZE-1, P-III BLAZE-2, and ACTIV-2 study. These trials are not affected by the enrollment pause in the ACTIV-3 clinical trial

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly

The post Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns first appeared on PharmaShots.

Analysis of Recent National Trends in Medicaid and CHIP Enrollment

This data note looks at national and state-by-state Medicaid and CHIP preliminary enrollment data through May 2020, as states were still in the early stages of experiencing the health and economic effects of the coronavirus pandemic. Data show that after declines in enrollment from December 2017 through December 2019, total enrollment grew to 73.5 million in May, an increase of 0.8 million from April 2020 (1%) and 2.3 million from February (3.2%), right before the pandemic. These early data suggest that recent increases in enrollment may be reversing previous trends of flat or negative enrollment growth.

Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in Clinical Trial of MRTX849 for Patients with Advanced Solid Tumors

Shots:

  • The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation
  • Strata Oncology will identify patients to be considered for enrollment into Mirati’s P-I/II study. The Strata Trial provides tumor molecular profiling for patients with advanced cancer paired with a portfolio of biomarker-guided clinical trials
  • Strata Oncology utilizes StrataNGS which is a molecular profiling test optimized for performance on tumor tissue samples as small as 0.5mm2 surface area. MRTX849 is a novel KRAS G12C selective inhibitor

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Strata Oncology